Correlation Between Various Adipokines and Vascular Inflammation Measured by Positron Emission Tomography (PET) With 18F-fluoro-deoxyglucose (FDG) (18FDG-PET)

Correlation Between Various Adipokines and Vascular Inflammation Measured by 18FDG-PET In Healthy Male Subjects

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01150006

Enrollment

Registered

2010-06-24

Start date

2010-04-30

Completion date

2010-06-30

Last updated

2010-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis

Keywords

atherosclerosis, vascular inflammation, adipocyte fatty acid binding protein, adiponectin, leptin, 18FDG-PET

Brief summary

The inflammatory state and composition of atherosclerotic plaques are considered the main contributing factors responsible for acute cardiovascular events, rather than the degree of stenosis. Recently, positron emission tomography (PET) with 18F-fluoro-deoxyglucose (FDG) has been suggested as a promising novel imaging technique to identify the inflammatory state of atherosclerotic plaque. Recently, a few clinical studies showed that circulating A-FABP level had a close relation with the development of atherosclerosis in human. Therefore, in the present study, the investigators examined the relationship between circulating A-FABP and vascular inflammation of carotid arteries measured using FDG-PET in healthy male subjects.

Interventions

OTHERCross sectional study

This is not intervention study. The purpose of the study is to examine the relationship between various adipokine levels and PET imaging at the cross section setting

Study design

Observational model

CASE_ONLY

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

MALE

Age

20 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy male volunteers for visiting routine medical check in our clinic

Exclusion criteria

* History of cardiovascular disease (myocardial infarction, unstable angina,stroke, or cardiovascular revascularization) * Diabetes * Hypertension * Malignancy * Severe renal or hepatic disease * Subjects taking medications that might affect inflammation such as NSIAD and statin

Design outcomes

Primary

Measure	Time frame
Vascular inflammation in carotid arterial wall, represented as the target-to-background ratio (TBR), using FDG-PET	12 weeks

Secondary

Measure	Time frame
Circulating serum A-FABP levels	12 weeks
Circulating serum leptin levels	12weeks
Circulating serum adiponectin levels	12 weeks
Carotid intima-media thickness levels measured using ultrasonography	12 weeks

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026